ArticleInternational journal of molecular sciences2025
Computational Phenotypic Drug Discovery for Anticancer Chemotherapy: PTML Modeling of Multi-Cell Inhibitors of Colorectal Cancer Cell Lines.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- KansFormer network based on a multimodal cross-attention mechanism for drug-target interaction prediction.Molecular diversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Colorectal cancer is one of the most dangerous neoplastic diseases in terms of both mortality and incidence. Thus, anti-colorectal cancer agents are urgently needed. Computational approaches have great potential to accelerate the phenotypic discovery of versatile anticancer agents. Here, by combining perturbation-theory machine learning (PTML) modeling with the fragment-based topological design (FBTD) approach, we provide key computational evidence on the computer-aided de novo design and prediction of new molecules virtually exhibiting multi-cell inhibitory activity against different colorectal cancer cell lines. The PTML model created in this study achieved sensitivity and specificity values exceeding 80% in training and test sets. The FBTD approach was employed to physicochemically and structurally interpret the PTML model. These interpretations enabled the rational design of six new drug-like molecules, which were predicted as active against multiple colorectal cancer cell lines by both our PTML model and a CLC-Pred 2.0 webserver, with the latter being a well-established virtual screening tool for early anticancer discovery. This work confirms the potential of the joint use of PTML and FBTD as a unified computational methodology for early phenotypic anticancer drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.